Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours
About this trial
The SOURCE Lung trial is currently open at:
- St. Luke’s Radiation Oncology Network (SLRON)
- The Beacon Hospital
- St. Luke’s Radiation Oncology Network (SLRON)
What is the goal of this study?
The goal of the study is to determine the safety of delivering SABR treatment to ultracentral lung tumours. An ultracentral lung tumour is a tumour that is positioned near the windpipe, heart or the major blood vessels near the heart. These tumours are more challenging for us to treat because they are near such important organs which we want to protect. The SOURCE study is investigating the safety of treating these tumours with high-dose precise radiotherapy called Stereotactic Ablative Radiation Therapy. (SABR)
What happens to patients as part of this trial?
- SABR is a modern form of radiotherapy that delivers very high-dose treatment in just less hospital visits than standard radiotherapy.
- If a patient joins this study they will receive 8 treatment sessions of high-dose radiation to their ultracentral lung tumour.
- We use advanced planning techniques to reduce the radiation to the windpipe, heart and vessels near the heart while also giving a high dose of radiation to the tumour.
- Patients will then be followed up by their radiation oncologist and the clinical trials team for 5 years to assess any side-effects of treatment.
- The study is investigating wthe safety of delivering SABR treatment to ultracentral tumours.
Here is a video explaining more about SABR treatment:
Who can take part?
You may be eligible if:
- You are 18 or older,
- You have early stage lung cancer or a single oligometastatic lung lesions (this means a cancer lesion which has spread from another part of the body).
- Your tumour is positioned near your windpipe, heart of the vessels of the heart.
- You meet other medical criteria checked by your team which means you are a suitable candidate to receive SABR treament.
Study Oversight
Professor John Armstrong is the Chief Investigator of this study.
The study is sponsored by Cancer Trials Ireland.
This is an Irish led study designed by Professor Armstrong, and developed with the input of the team at SLRON and Cancer Trials Ireland.